Shots:
- The US FDA has granted IND clearance for RAG-1C for the prevention & treatment of Proliferative Vitreoretinopathy (PVR)
- The P-I trial will assess the safety, tolerability, PK, & preliminary efficacy of RAG-1C in patients undergoing surgery for retinal detachment who are at high risk of developing PVR
- RAG-1C is an intravitreal saRNA therapy using Ractigen’s LiCO platform to reactivate endogenous p21 (CDKN1A) gene, inducing cell cycle arrest to inhibit proliferation & myofibroblast transformation, with the potential for long-lasting “one-and-done” anti-fibrotic protection
Ref: PRnewswire | Image: Ractigen | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
